Researchers at the Virginia Commonwealth University’s Masey Cancer Center have developed an innovative approach to the treatment of multiple myeloma. The Phase II Clinical trial involves a process to ‘mark’ cancerous cells and also boost the body’s immune system – by removing the patient’s stem cells, manipulating them in-vitro [outside the body] and then reintroducing the stem cells back into the patient - to destroy the cancerous cells. Researchers believe the reprogrammed stem cells will also prevent any future recurrence of multiple myeloma.
StemSave Blog
Autologous Stem Cells Utilized in Phase II Clinical Trial to Treat Multiple Myeloma
Posted by pamela@stemsave.com on Nov 8, 2012 5:00:27 AM
0 Comments Click here to read/write comments
Topics: clinical trials, multiple myeloma, Phase II, Stemcells, stemsaveblog